Literature DB >> 9888211

Severe viral respiratory infections in infants with cystic fibrosis.

D Armstrong1, K Grimwood, J B Carlin, R Carzino, J Hull, A Olinsky, P D Phelan.   

Abstract

Limited data in children with cystic fibrosis (CF) suggest that respiratory viral infections during infancy result in substantial morbidity. Eighty of 101 (79%) infants with CF diagnosed by neonatal screening during 1991-1996 were recruited into a prospective, multiple-birth cohort study. We aimed to perform an initial, then annual bronchoalveolar lavage (BAL) for bacterial and viral culture, cytology, IL-8, and elastolytic activity over the following 2 years. When possible, BAL was also performed during any hospitalization for a pulmonary exacerbation, and additional specimens for viral culture were collected by nasopharyngeal aspiration. Thirteen infants undergoing bronchoscopy for congenital stridor served as disease controls. During infancy, 31 children (39%) were hospitalized for respiratory disease and 20 (65%) cases had an etiologic agent identified. Respiratory viruses were detected in 16/31 (52%) cases, including four with simultaneous bacterial infection. Another four were infected with Staphylococcus aureus. Respiratory syncytial virus predominated and was found in seven infants. In the absence of bacteria, those with viral infections had acute onset of respiratory distress, were not treated with antibiotics, and had an uncomplicated hospital course. Compared to noninfected CF subjects and controls, infected infants had elevated BAL inflammatory indices (P < 0.01). Eleven of 31 (35%) hospitalized infants followed for 12-60 months acquired Pseudomonas aeruginosa, compared with only three of 49 (6%) subjects not hospitalized for respiratory symptoms during infancy (risk ratio 5.8, CI 1.9, 24). We conclude that respiratory viruses are important causes of hospitalization in CF infants. While viral infections were self-limited, they were accompanied by airway inflammatory changes, and admission to hospital was associated with early acquisition of Pseudomonas aeruginosa and persistent respiratory symptoms.

Entities:  

Mesh:

Year:  1998        PMID: 9888211     DOI: 10.1002/(sici)1099-0496(199812)26:6<371::aid-ppul1>3.0.co;2-n

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  64 in total

1.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 3.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

4.  Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors:  Mukta Jain; Anne H Thomson
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

5.  Influenza vaccination in children at high risk of respiratory disease.

Authors:  Maria Francesca Patria; Claudia Tagliabue; Benedetta Longhi; Susanna Esposito
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 6.  Effects of airway surface liquid pH on host defense in cystic fibrosis.

Authors:  Abigail R Berkebile; Paul B McCray
Journal:  Int J Biochem Cell Biol       Date:  2014-02-19       Impact factor: 5.085

7.  Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.

Authors:  Clélia Buchs; Marie-Laure Dalphin; Stéphane Sanchez; Marie Perceval; Laurianne Coutier; Catherine Mainguy; Behrouz Kassaï-Koupaï; Philippe Reix
Journal:  Eur J Pediatr       Date:  2017-05-16       Impact factor: 3.183

8.  Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.

Authors:  V Jullien; D Hubert; O Launay; G Babany; O Lortholary; I Sermet
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

9.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis.

Authors:  Megan W France; Szeanna Tai; Phillip J Masel; Vanessa L Moore; Tracy L McMahon; Alexander J Ritchie; Scott C Bell
Journal:  BMC Pulm Med       Date:  2010-02-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.